



Use of Long-acting Injectable Antipsychotics for the Treatment of Bipolar I Disorder: Relevant Questions from Providers

This program is paid for by Otsuka
Pharmaceutical Development &
Commercialization, Inc. (OPDC) and
Lundbeck, LLC.

Speakers are paid consultants for Otsuka
Pharmaceutical Development &
Commercialization, Inc.

PsychU Webinar Rules Of Engagement

- Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Lundbeck, LLC. have entered into collaboration with *OPEN MINDS*, to explore new ways of bringing/increasing awareness around serious mental illness.
- OPDC/Lundbeck's interaction with *OPEN MINDS* is through PsychU, an online, non-branded portal dedicated to providing information and resources on important disease state and care delivery topics related to mental illness. One of the methods employed for the sharing of information will be the hosting of webinars. Webinars conducted by OPDC/Lundbeck are based on the following parameters:
- When conducting medical dialogue, whether by presentation or debate, OPDC/Lundbeck and/or its paid consultants aim to provide the viewer with information that is accurate, not misleading, scientifically rigorous, and does not promote OPDC/Lundbeck products.
No continuing medical education (CME) credits are available for any PsychU program.
- OPDC/Lundbeck and/or their paid consultants do not expect to be able to answer every question or comment during a PsychU webinar; however, they will do their best to address important topics and themes that arise.
- OPDC/Lundbeck and/or their paid consultants are not able to provide clinical advice or answer questions relating to specific patient's condition.
- Otsuka and Lundbeck employees and contractors should not participate in this program (e.g., submit questions or comments) unless they have received express approval to do so from Otsuka Legal Affairs.
- OPDC/Lundbeck operate in a highly regulated and scrutinized industry. Therefore, we may not be able to discuss every issue or topic that you are interested in, but we will do our best to communicate openly and directly. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind.

Our Featured Speakers



Joseph Goldberg, MD

Clinical Professor of Psychiatry, Icahn School of Medicine at Mount Sinai

Dr. Goldberg currently serves as the Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and as President Elect of the American Society of Clinical Psychopharmacology. He has an extensive academic research background studying the features and treatment of mood disorders, including bipolar disorder and other forms of depression. Dr. Goldberg has published over 200 peer-reviewed papers on topics related to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology.



Mauricio Tohen, MD, DrPH, MBA

Distinguished University Professor and Chairman, Department of Psychiatry and Behavioral Sciences, University of New Mexico

Dr. Tohen is a Distinguished University Professor at the University of New Mexico and the Chairman of the University of New Mexico's Department of Psychiatry and Behavioral Sciences. With more than 350 publications and 20,000 scientific citations to his name. In 2017, Dr Tohen was recognized in expertscape as Top 0.12% Expertise in Bipolar Disorder Worldwide based in published articles from 2007-2017.

Objectives

Objective 1

Describe the challenges to long-term treatment and the importance of management options for patients living with Bipolar I Disorder (BP-I)



Objective 2

Discuss the pros and cons of LAIs for patients living with BP-I, from the provider and patient perspective



Objective 3

Understand strategies to aid in shared decision making between providers and patients when considering LAIs

What are the goals of long-term management of bipolar I disorder?

What are the perceived advantages (positives) and disadvantages (negatives) of LAIs for patients living with bipolar I disorder?



LAIs – Long-Acting Injectables

How should providers be discussing switching to an LAI for patients living with bipolar I disorder?



LAI – Long-Acting Injectable



What should be considered when choosing the dosing interval of an LAI for patients living with bipolar I disorder?



LAI – Long-Acting Injectable

Questions?

For more information or to request a more detailed live presentation on this topic from your local Clinical Science Liaison, please visit www.PsychU.org/events

www.PsychU.org

Get Your Resources On The Go

Download the **PsychU App** from Google Play or from the Apple App Store!



Subscribe to **The PsychU Community Podcast** on the Google Podcasts app or on the Apple Podcasts app.



Use of Long-acting Injectable Antipsychotics for the Treatment of Bipolar I Disorder: Relevant Questions from Providers